Amneal Enters U.S. Biosimilars Market With Approval of RELEUKO (filgrastim-ayow)
Amneal Pharmaceuticals, Inc. announced the U.S. Food and Drug Administration (FDA) approval of the Biologics License ...
Read moreAmneal Pharmaceuticals, Inc. announced the U.S. Food and Drug Administration (FDA) approval of the Biologics License ...
Read moreAmneal Pharmaceuticals, Inc. announced the approval of four generic injectables products. Dexamethasone sodium phosphate injection, USP ...
Read moreAmneal announced that the FDA accepted Amneal’s 505(b)(2) NDA for a newly licensed dihydroergotamine (DHE) prefilled ...
Read moreQ1 2021 Net Revenue of $493 million; GAAP Net Income of $7 million; Diluted Income per ...
Read moreAmneal Pharmaceuticals, Inc. and Kashiv BioSciences LLC today announced that Amneal Pharmaceuticals LLC , a subsidiary ...
Read moreAddress: | Pharma Reg News, First floor, Shop no.1 , Plot no 241,242, Near Fire station, GIDC, Ankleshwar, Gujarat - 393002. |
Phone: | +91 8511586232, +91 9029066605 |
Email: | author@pharmaregnews.com |
© 2021 - Pharmaregnews.com. Developed by YESWEUS.
© 2021 - Pharmaregnews.com. Developed by YESWEUS.